Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Edgewise Therapeutics Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
EWTX
Nasdaq
8731
https://edgewisetx.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Edgewise Therapeutics Inc
Edgewise Therapeutics Inc (EWTX) Reports First Quarter 2024 Financial Results
- May 10th, 2024 5:38 pm
Edgewise Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference on May 15, 2024
- May 10th, 2024 12:00 pm
Edgewise Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights
- May 9th, 2024 12:00 pm
Edgewise Therapeutics Appoints Arlene Morris to its Board of Directors
- May 7th, 2024 12:00 pm
Edgewise Therapeutics doses first subject in HCM drug trial
- May 7th, 2024 9:02 am
Edgewise Therapeutics Doses First Patient in Phase 2 CIRRUS-HCM Trial of EDG-7500 in Obstructive Hypertrophic Cardiomyopathy (HCM)
- May 6th, 2024 12:00 pm
Edgewise Receives European Medicines Agency (EMA) Orphan Drug Designations for Sevasemten (EDG-5506) for the Treatment of Becker and Duchenne Muscular Dystrophies
- Apr 23rd, 2024 12:00 pm
Edgewise Therapeutics Announces Positive Two-Year Topline Results from the ARCH Open Label Trial of Sevasemten (EDG-5506) in Adults with Becker Muscular Dystrophy (Becker)
- Apr 15th, 2024 8:05 pm
Edgewise Therapeutics Announces Upcoming Podium Presentation at the American College of Cardiology's 2024 Annual Scientific Session
- Mar 28th, 2024 12:00 pm
Edgewise Therapeutics to Present at the Cantor Virtual Muscular Dystrophy Symposium on April 2, 2024
- Mar 27th, 2024 12:00 pm
Edgewise Therapeutics to Present at the Leerink Partners Global Biopharma Conference on March 11, 2024
- Mar 5th, 2024 1:00 pm
Edgewise Therapeutics to Present on EDG-5506 for the Treatment of Becker Muscular Dystrophy at the 2024 MDA Clinical and Scientific Conference
- Feb 28th, 2024 1:00 pm
Wall Street Analysts Predict a 52.78% Upside in Edgewise Therapeutics, Inc. (EWTX): Here's What You Should Know
- Feb 26th, 2024 2:55 pm
Edgewise Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
- Feb 22nd, 2024 1:00 pm
13 Best Booming Stocks to Buy Right Now
- Feb 21st, 2024 2:21 pm
Edgewise Receives U.S. FDA Fast Track Designation for EDG-5506 for the Treatment of Duchenne Muscular Dystrophy (Duchenne)
- Feb 13th, 2024 1:00 pm
Insider Favorites: 7 Stocks with Bullish Buying Signals
- Feb 11th, 2024 7:55 pm
Wall Street Analysts See a 33.27% Upside in Edgewise Therapeutics, Inc. (EWTX): Can the Stock Really Move This High?
- Feb 9th, 2024 2:55 pm
Edgewise Therapeutics Inc CFO R Carruthers Sells 90,000 Shares
- Jan 26th, 2024 3:04 am
Wall Street Analysts Think Edgewise Therapeutics, Inc. (EWTX) Could Surge 70.76%: Read This Before Placing a Bet
- Jan 24th, 2024 2:55 pm
Scroll